کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3335883 | 1213548 | 2010 | 7 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation](/preview/png/3335883.png)
Leukemia relapse is a serious therapeutic challenge following hematopoietic stem cell transplantation (HSCT). In this retrospective study, 23 patients [15 (65.2%) AML, 8 (34.8%) ALL] who received DLI ± reinduction chemotherapy for post-transplant relapse were reviewed. The overall response rate of DLI was 66.7% for AML and 50% for ALL. A total of 15 patients (65.2%) developed acute graft versus host disease (GVHD). Response rates were higher in patients with GVHD (80% versus 25%; p = 0.01; OR: 12.0). The probability of OS was better in patients who respond to DLI (p = 0.04). Further strategies are required to improve the anti-tumor properties of alloreactive donor lymphocytes and to obtain durable responses with DLI in patients with relapsed acute leukemia after allogeneic HSCT.
Journal: Transfusion and Apheresis Science - Volume 42, Issue 3, June 2010, Pages 239–245